Literature DB >> 30114337

Patterns of failure following the excision of in-transit lesions in melanoma and the influence of excisional margins.

Alexandra B Gonzalez1,2, Christian L Baum3, Jerry D Brewer3, Christopher J Arpey3, William S Harmsen4, Vera J Suman4, Svetomir N Markovic5, James W Jakub2.   

Abstract

BACKGROUND AND OBJECTIVES: To describe the patterns of failure in patients with in-transit (IT) melanoma undergoing surgical excision.
METHODS: A retrospective review of patients who underwent their first IT lesion(s) resection between May 2005 and September 2014. Cumulative incidence of local failure (new lesion within 2 cm of IT resection) was estimated. Associations between clinicopathologic characteristics, local failure, and any recurrence were analyzed.
RESULTS: One hundred and thirty patients presented to our institution with IT disease over the study period and met the inclusion criteria. The 2-year cumulative incidence of local failure was 19.5%. Twenty-four patients developed disease within 2 cm of the resected IT disease; however, only eight were isolated local events. Cumulative incidence of local failure and of any disease differed with respect to less than 1 year disease-free interval (DFI) from primary melanoma to first IT event, and having greater than 1 IT lesion at presentation. Incidence of local failure was not found to differ with respect to gross margin greater than 5 mm, after adjusting for DFI and greater than 1 IT lesions.
CONCLUSIONS: Patients with greater than 1 IT lesion and a DFI less than 1 year are at a higher risk of failure after surgical excision of a first IT event. Very few failures were isolated local disease within 2 cm of the IT resection scar, regardless of IT excision margin.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  disease-free interval; in-transit melanoma; local recurrence; satellites; stage III

Mesh:

Year:  2018        PMID: 30114337      PMCID: PMC6175616          DOI: 10.1002/jso.25176

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  13 in total

1.  Major amputation for malignant melanoma: an epidemiological study.

Authors:  L B Ebskov
Journal:  J Surg Oncol       Date:  1993-02       Impact factor: 3.454

2.  In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy.

Authors:  Rebecca L Read; Lauren Haydu; Robyn P M Saw; Michael J Quinn; Kerwin Shannon; Andrew J Spillane; Jonathan R Stretch; Richard A Scolyer; John F Thompson
Journal:  Ann Surg Oncol       Date:  2014-09-26       Impact factor: 5.344

3.  Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial.

Authors:  C P Karakousis; C M Balch; M M Urist; M M Ross; T J Smith; A A Bartolucci
Journal:  Ann Surg Oncol       Date:  1996-09       Impact factor: 5.344

4.  Major amputation for advanced malignant melanoma.

Authors:  D P Jaques; D G Coit; M F Brennan
Journal:  Surg Gynecol Obstet       Date:  1989-07

5.  The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

Authors:  Stephen B Edge; Carolyn C Compton
Journal:  Ann Surg Oncol       Date:  2010-06       Impact factor: 5.344

6.  Analysis of prognosis and disease progression after local recurrence of melanoma.

Authors:  X D Dong; D Tyler; J L Johnson; P DeMatos; H F Seigler
Journal:  Cancer       Date:  2000-03-01       Impact factor: 6.860

7.  Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy.

Authors:  Timothy M Pawlik; Merrick I Ross; Marcella M Johnson; Christopher W Schacherer; Dana M McClain; Paul F Mansfield; Jeffrey E Lee; Janice N Cormier; Jeffrey E Gershenwald
Journal:  Ann Surg Oncol       Date:  2005-06-16       Impact factor: 5.344

8.  Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma.

Authors:  J E Gershenwald; M I Colome; J E Lee; P F Mansfield; C Tseng; J J Lee; C M Balch; M I Ross
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

9.  Verification of a formula for determination of preexcision surgical margins from fixed-tissue melanoma specimens.

Authors:  M K Silverman; F M Golomb; A W Kopf; C M Grin-Jorgensen; K A Vossaert; J P Doyle; M J Levenstein
Journal:  J Am Acad Dermatol       Date:  1992-08       Impact factor: 11.527

10.  Status of the Regional Nodal Basin Remains Highly Prognostic in Melanoma Patients with In-Transit Disease.

Authors:  Alexandra B Gonzalez; James W Jakub; William S Harmsen; Vera J Suman; Svetomir N Markovic
Journal:  J Am Coll Surg       Date:  2016-03-26       Impact factor: 6.113

View more
  3 in total

1.  Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death.

Authors:  Prathamesh M Kulkarni; Eric J Robinson; Jing Wang; Yvonne M Saenger; Jaya Sarin Pradhan; Robyn D Gartrell-Corrado; Bethany R Rohr; Megan H Trager; Larisa J Geskin; Harriet M Kluger; Pok Fai Wong; Balazs Acs; Emanuelle M Rizk; Chen Yang; Manas Mondal; Michael R Moore; Iman Osman; Robert Phelps; Basil A Horst; Zhe S Chen; Tammie Ferringer; David L Rimm
Journal:  Clin Cancer Res       Date:  2019-10-21       Impact factor: 12.531

2.  Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma.

Authors:  Robyn D Gartrell; Douglas K Marks; Emanuelle M Rizk; Margaret Bogardus; Camille L Gérard; Luke W Barker; Yichun Fu; Camden L Esancy; Gen Li; Jiayi Ji; Shumin Rui; Marc S Ernstoff; Bret Taback; Sarabjot Pabla; Rui Chang; Sandra J Lee; John J Krolewski; Carl Morrison; Basil A Horst; Yvonne M Saenger
Journal:  Clin Cancer Res       Date:  2019-01-15       Impact factor: 12.531

3.  Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases.

Authors:  Anna K Lawless; David J Coker; Serigne N Lo; Tasnia Ahmed; Richard A Scolyer; Sydney Ch'ng; Omgo E Nieweg; Kerwin Shannon; Andrew Spillane; Jonathan R Stretch; John F Thompson; Robyn P M Saw
Journal:  Ann Surg Oncol       Date:  2022-06-30       Impact factor: 4.339

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.